
|Articles|August 1, 2002
Supplements and Featured Publications
- Measuring Persistency with Drug Therapy in Glaucoma Management
- Volume 8
- Issue 10 Suppl
An Economic Analysis of Switching to Latanoprost from a Beta-Blocker or adding Brimonidine or Latanoprost to a Beta-Blocker in Open-Angle Glaucoma or Ocular Hypertension
Advertisement
Articles in this issue
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Trump Strikes 9 New Pricing Agreements as Drugmakers Navigate Tariff, Regulatory Pressure
2
Fuzuloparib Monotherapy Improves PFS in Advanced Ovarian Cancer, but Adding Apatinib Offers No Additional Benefit
3
Top 5 Inflammation Articles of 2025
4
House Republicans Block Vote on ACA Subsidy Extension
5








































